Alnylam Pharmaceuticals, the company that turned RNA interference from a Nobel-winning observation into six approved drugs, has signed its first dedicated AI-discovery collaboration. The partner is Inceptive, the RNA-design startup co-founded by former Google transformer researcher Jakob Uszkoreit. The deal, announced June 3, is worth up to $2 billion — but only $30 million of that is committed today.
The economics follow the now-familiar AI-biotech template: a modest upfront against a large, back-loaded headline. The $30 million combines cash and an equity investment in Inceptive. Everything beyond it is contingent on Inceptive earning preclinical, regulatory, and commercial-sales milestones across the programs the two companies pursue together. Royalty terms were not disclosed.
What each side brings
The collaboration aims to advance siRNA design by modeling target mRNAs and jointly searching sequence space for novel chemical modifications. Alnylam supplies the asset that is hardest to replicate: more than 20 years of proprietary siRNA data and an R&D engine with six approvals behind it. Inceptive supplies what it calls AI “foundation models of life” — sequence-based models meant to replace some of the trial-and-error screening of thousands of molecules.
“Most drug design still works through a process of trial and error, testing thousands of molecules.” — Jakob Uszkoreit, Inceptive
The number of targets and programs was not specified. Notably, neither company has reported a molecule, an animal result, or a development candidate from the partnership — this is a discovery-stage bet on a method, not on data. Whether AI sequence design beats Alnylam’s established chemistry is precisely the question the next several years are meant to answer.